Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms

Bristol Myers Squibb and AstraZeneca are reportedly in talks regarding a potential mega-merger that would create the largest pharmaceutical company in history, though analysts remain skeptical due to significant antitrust concerns and potential product overlap in oncology. Meanwhile, the pharmaceutical industry navigates a busy second-quarter earnings season, highlighted by Pfizer’s ongoing cost-reduction initiatives and Merck’s mixed clinical results for its anti-TL1 antibody, tuliscobart. Regulatory scrutiny remains intense, as evidenced by recent FDA advisory committee meetings. Capricor Therapeutics faced a negative vote regarding its cell therapy for Duchenne muscular dystrophy amid statistical analysis disputes, while Replimune’s immunotherapy for advanced melanoma received support from advisors. These developments underscore the ongoing tension between industry innovation and regulatory requirements, as the FDA continues to refine its approach to drug approvals in the rare disease space.